Table A26:
Change in Depression Scores—Sub-population Analyses by Genetic Test Interpretive Report Classification for Baseline Medications
| Author, Year (Primary Publication) | Interpretive Report Bin Classification at Baselined (N PGx/TAU) | Measure | % Decrease | P Value | |
|---|---|---|---|---|---|
| PGx | TAU | ||||
| GeneSight | |||||
| Thase et al, 201968 (Greden et al, 201957) | Reda or Yellowb (357/430)d Reda or Yellowb + switched medication (235/225)d |
HAM-D17 | 27.1 30.0 |
22.1 22.3 |
.029 .11 |
| Dunlop et al, 201966 (Greden et al, 201957) | Yellowb or Reda (357/429) | HAM-D6 | 28.6 | 21.3 | .004 |
| Winner et al, 201365 | Greenc (6/6) Yellowb (11/8) Reda (7/6) Yellowb or Reda (18/14) |
HAM-D17 | NE NE 33.1 NR |
NE NE 0.8 NR |
.79 .23 .06 .03 |
| Hall-Flavin et al, 201355 | Greenc,d (17/21) Yellowb,d (31/42) Reda,d (16/18) |
HAM-D17 | NE NE 42.5 |
NE NE 16.6 |
.05 .12 .01 |
| Greenc,d (17/21) Yellowb,d (31/42) Reda,d (16/18) |
QIDS-C16 | NE NE 41.9 |
NE NE 11 |
.09 .02 .004 |
|
Abbreviations: Δ, change from baseline; HAM-D17, 17-item Hamilton Depression Rating Scale; NE, not estimated from graph; NS, not significant; PGx, pharmacogenomic-guided treatment; QIDS-C16, 16-item Quick Inventory Depression Scale, clinician-rated; TAU, treatment as usual.
a
Red – Use with caution and more frequent monitoring.
b
Yellow – Use with caution
c
Green – Use as directed.
d
Patients who were taking more than one medication at baseline were classified based on their most severe classification. Analyses excluded patients who were taking medications that were not included on test report.